Antithrombotic therapy for lower extremity artery disease: is more intense therapy required?

Affiliations

¹ Department of Cardiovascular Medicine, Graduate School of Medicine Kyoto University, Kyoto, Japan.
² Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Editorial

Junichi Tazaki et al. Eur Heart J Cardiovasc Pharmacother. 2020.

. 2020 Apr 1;6(2):94-96.

doi: 10.1093/ehjcvp/pvz044.

¹ Department of Cardiovascular Medicine, Graduate School of Medicine Kyoto University, Kyoto, Japan.
² Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

No abstract available

Comment on

Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases.
Savarese G, Reiner MF, Uijl A, D'Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, Lewis BS. Savarese G, et al. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):86-93. doi: 10.1093/ehjcvp/pvz036. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31392312